Astrocyte barriers to neurotoxic inflammation

Nature Reviews Neuroscience

Volumn 16, Issue 5, 2015, Pages 249-263

  Sofroniew, Michael V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; AUTOIMMUNE DISEASE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN INFECTION; BRAIN INJURY; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; ENCEPHALITIS; GLIA LIMITANS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE AGGREGATION; LEUKOCYTE MIGRATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; ANIMAL; CELL COMMUNICATION; CENTRAL NERVOUS SYSTEM DISEASES; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

AUTACOID;

ANIMALS; ASTROCYTES; CELL COMMUNICATION; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEURONS;

EID: 84928122606     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3898     Document Type: Review

References (137)

1. Burda, J. E. & Sofroniew, M. V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229-248 (2014).
2. Goverman, J. Autoimmune T cell responses in the central nervous system. Nature Rev. Immunol. 9, 393-407 (2009).
3. Ransohoff, R. M. & Engelhardt, B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nature Rev. Immunol. 12, 623-635 (2012).
4. Prinz, M. & Priller, J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nature Rev. Neurosci. 15, 300-312 (2014).
5. Barres, B. A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430-440 (2008).
6. Sofroniew, M. V. & Vinters, H. V. Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35 (2010).
7. Sofroniew, M. V. Astrogliosis. Cold Spring Harb. Perspect. Biol. 7, a020420 (2014).
8. Pekny, M. & Nilsson, M. Astrocyte activation and reactive gliosis. Glia 50, 427-434 (2005).
9. Sofroniew, M. V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638-647 (2009).
10. Kang, W. & Hebert, J. M. Signaling pathways in reactive astrocytes, a genetic perspective. Mol. Neurobiol. 43, 147-154 (2011).
11. Anderson, M. A., Ao, Y. & Sofroniew, M. V. Heterogeneity of reactive astrocytes. Neurosci. Lett. 565, 23-29 (2014).
12. Sofroniew, M. V. Reactive astrocytes in neural repair and protection. Neuroscientist 5, 400-407 (2005).
13. Silver, J. & Miller, J. H. Regeneration beyond the glial scar. Nature Rev. Neurosci. 5, 146-156 (2004).
14. Hamby, M. E. & Sofroniew, M. V. Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 7, 494-506 (2010).
15. Verkhratsky, A. et al. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 4, e00082 (2012).
16. Bianchi, M. G., Bardelli, D., Chiu, M. & Bussolati, O. Changes in the expression of the glutamate transporter EAAT3/EAAC1 in health and disease. Cell. Mol. Life Sci. 71, 2001-2015 (2014).
17. Kono, H. & Rock, K. L. How dying cells alert the immune system to danger. Nature Rev. Immunol. 8, 279-289 (2008).
18. Janeway, C. A. Jr & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
19. Iwasaki, A. & Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 327, 291-295 (2010).
20. Galea, I., Bechmann, I. & Perry, V. H. What is immune privilege (not) Trends Immunol. 28, 12-18 (2007).
21. Owens, T., Bechmann, I. & Engelhardt, B. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 67, 1113-1121 (2008).
22. Broadwell, R. D. & Sofroniew, M. V. Serum proteins by-pass the blood brain barrier for extracellular entry to the CNS. Exp. Neurol. 120, 246-263 (1993).
23. Engelhardt, B. & Coisne, C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 8, 4 (2011).
24. Wilson, E. H., Weninger, W. & Hunter, C. A. Trafficking of immune cells in the central nervous system. J. Clin. Invest. 120, 1368-1379 (2010).
25. Kawano, H. et al. Role of the lesion scar in the response to damage and repair of the central nervous system. Cell Tissue Res. 349, 169-180 (2012).
26. Wanner, I. B. et al. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. J. Neurosci. 33, 12870-12886 (2013).
27. Norton, W.T., Aquino, D.A., Hozumi, I., Chiu, F.C. & Brosnan, C.F. Quantitative aspects of reactive gliosis: a review. Neurochem. Res. 17, 877-885 (1992).
28. Bush, T. G. et al. Leukocyte infiltration, neuronal degeneration and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23, 297-308 (1999).
29. Bush, T. G. et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 93, 189-201 (1998).
30. Faulkner, J. R. et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24, 2143-2155 (2004).
31. Li, L. et al. Protective role of reactive astrocytes in brain ischemia. J. Cereb. Blood Flow Metab. 28, 468-481 (2008).
32. Voskuhl, R. R. et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J. Neurosci. 29, 11511-11522 (2009).
33. Toft-Hansen, H., Fuchtbauer, L. & Owens, T. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease. Glia 59, 166-176 (2011).
34. Liu, Z. et al. Beneficial effects of gfap/vimentin reactive astrocytes for axonal remodeling and motor behavioral recovery in mice after stroke. Glia 62, 2022-2033 (2014).
35. Brosnan, C. F. & Raine, C. S. The astrocyte in multiple sclerosis revisited. Glia 61, 453-465 (2013).
36. Eddleston, M. & Mucke, L. Molecular profile of reactive astrocytes-implications for their role in neurological disease. Neuroscience 54, 15-36 (1993).
37. Zamanian, J. L. et al. Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391-6410 (2012).
38. Hamby, M. E. et al. Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors. J. Neurosci. 32, 14489-14510 (2012).
39. John, G. R., Lee, S. C., Song, X., Rivieccio, M. & Brosnan, C. F. IL-1-regulated responses in astrocytes: relevance to injury and recovery. Glia 49, 161-176 (2005).
40. Brambilla, R. et al. Inhibition of astroglial nuclear factor B reduces inflammation and improves functional recovery after spinal cord injury. J. Exp. Med. 202, 145-156 (2005).
41. Okada, S. et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nature Med. 12, 829-834 (2006).
42. Brambilla, R. et al. Transgenic inhibition of astroglial NF-B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J. Immunol. 182, 2628-2640 (2009).
43. Kim, R. Y. et al. Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune encephalomyelitis. J. Neuroimmunol. 274, 53-61 (2014).
44. Moreno, M. et al. Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. J. Neurosci. 34, 8175-8185 (2014).
45. Ko, E. M. et al. Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model. J. Neuroinflammation 11, 105 (2014).
46. Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A. & John, G. R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc. Natl Acad. Sci. USA 106, 1977-1982 (2009).
47. Argaw, A. T. et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 122, 2454-2468 (2012).
48. Kang, Z. et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32, 414-425 (2010).
49. Xanthos, D. N. & Sandkuhler, J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nature Rev. Neurosci. 15, 43-53 (2014).
50. Abbott, N. J., Ronnback, L. & Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Rev. Neurosci. 7, 41-53 (2006).
51. Alvarez, J. I. et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 334, 1727-1731 (2011).
52. Alvarez, J. I., Katayama, T. & Prat, A. Glial influence on the blood brain barrier. Glia 61, 1939-1958 (2013).
53. Bell, R. D. et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516 (2012).
54. Herrmann, J. E. et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J. Neurosci. 28, 7231-7243 (2008).
55. Drogemuller, K. et al. Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. J. Immunol. 181, 2683-2693 (2008).
56. Haroon, F. et al. GP130-dependent astrocytic survival is critical for the control of autoimmune central nervous system inflammation. J. Immunol. 186, 6521-6531 (2011).
57. Middeldorp, J. & Hol, E. M. GFAP in health and disease. Prog. Neurobiol. 93, 421-443 (2011).
58. Liedtke, W., Edelmann, W., Chiu, F. C., Kucherlapati, R. & Raine, C. S. Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. Am. J. Pathol. 152, 251-259 (1998).
59. Macauley, S. L., Pekny, M. & Sands, M. S. The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis. J. Neurosci. 31, 15575-15585 (2011).
60. Kraft, A. W. et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J. 27, 187-198 (2013).
61. Norden, D. M., Fenn, A. M., Dugan, A. & Godbout, J. P. TGF produced by IL-10 redirected astrocytes attenuates microglial activation. Glia 62, 881-895 (2014).
62. Cekanaviciute, E. et al. Astrocytic transforming growth factor-beta signaling reduces subacute neuroinflammation after stroke in mice. Glia 62, 1227-1240 (2014).
63. Cekanaviciute, E. et al. Astrocytic TGF-signaling limits inflammation and reduces neuronal damage during central nervous system Toxoplasma infection. J. Immunol. 193, 139-149 (2014).
64. Min, K. J., Yang, M. S., Kim, S. U., Jou, I. & Joe, E. H. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J. Neurosci. 26, 1880-1887 (2006).
65. Kostianovsky, A. M., Maier, L. M., Anderson, R. C., Bruce, J. N. & Anderson, D. E. Astrocytic regulation of human monocytic/microglial activation. J. Immunol. 181, 5425-5432 (2008).
66. Mizee, M. R. et al. Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function in multiple sclerosis. Acta Neuropathol. 128, 691-703 (2014).
67. Catrysse, L., Vereecke, L., Beyaert, R. & van Loo, G. A20 in inflammation and autoimmunity. Trends Immunol. 35, 22-31 (2014).
68. Wang, X. et al. Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-B-and STAT1-dependent chemokine production in astrocytes. Acta Neuropathol. 126, 711-724 (2013).
69. Shao, W. et al. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via B-crystallin. Nature 494, 90-94 (2013).
70. Ousman, S. S. et al. Protective and therapeutic role for B-crystallin in autoimmune demyelination. Nature 448, 474-479 (2007).
71. Steelman, A. J., Smith, R. 3rd, Welsh, C. J. & Li, J. Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J. Biol. Chem. 288, 23776-23787 (2013).
72. Hutchison, E. R. et al. Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes. Glia 61, 1018-1028 (2013).
73. Spence, R. D. & Voskuhl, R. R. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front. Neuroendocrinol. 33, 105-115 (2012).
74. Spence, R. D. et al. Neuroprotection mediated through estrogen receptor-in astrocytes. Proc. Natl Acad. Sci. USA 108, 8867-8872 (2011).
75. Spence, R. D. et al. Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ER signaling on astrocytes but not through ER signaling on astrocytes or neurons. J. Neurosci. 33, 10924-10933 (2013).
76. Rot, A. & von Andrian, U. H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891-928 (2004).
77. Allen, C. D., Okada, T. & Cyster, J. G. Germinal-center organization and cellular dynamics. Immunity 27, 190-202 (2007).
78. Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Rev. Immunol. 6, 205-217 (2006).
79. Franciotta, D., Salvetti, M., Lolli, F., Serafini, B. & Aloisi, F. B cells and multiple sclerosis. Lancet Neurol. 7, 852-858 (2008).
80. Peters, A. et al. TH17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986-996 (2011).
81. Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188-2197 (2011).
82. Metcalf, T. U., Baxter, V. K., Nilaratanakul, V. & Griffin, D. E. Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis. J. Virol. 87, 2420-2429 (2013).
83. Pohl, M. et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol. Commun. 1, 85 (2013).
84. Yamagata, K., Nakayama, C. & Suzuki, K. Dietary-carotene regulates interleukin-1-induced expression of apolipoprotein E in astrocytes isolated from stroke-prone spontaneously hypertensive rats. Neurochem. Int. 62, 43-49 (2013).
85. Mahley, R. W. & Huang, Y. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 76, 871-885 (2012).
86. Halassa, M. M. & Haydon, P. G. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 72, 335-355 (2010).
87. Tong, X. et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nature Neurosci. 17, 694-703 (2014).
88. Sofroniew, M. V. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist 20, 160-172 (2014).
89. Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473-477 (2005).
90. Roemer, S. F. et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130, 1194-1205 (2007).
91. Saadoun, S. et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133, 349-361 (2010).
92. Howe, C. L. et al. Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia 62, 692-708 (2014).
93. Kitley, J. et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 71, 276-283 (2014).
94. Sato, D. K. et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82, 474-481 (2014).
95. Hoftberger, R. et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult. Scler. http://dx.doi. org/10.1177/1352458514555785 (2014).
96. Zamvil, S. S. & Slavin, A. J. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder Neurol. Neuroimmunol. Neuroinflamm. 2, e62 (2015).
97. Diamond, B., Huerta, P. T., Mina-Osorio, P., Kowal, C. & Volpe, B. T. Losing your nerves Maybe it's the antibodies. Nature Rev. Immunol. 9, 449-456 (2009).
98. Kowarik, M. C. et al. The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J. Neuroinflammation 12, 19 (2015).
99. Khakh, B. S. & Sofroniew, M. V. Astrocytes and Huntington's disease. ACS Chem. Neurosci. 5, 494-496 (2014).
100. Papadopoulos, M. C., Bennett, J. L. & Verkman, A. S. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nature Rev. Neurol. 10, 493-506 (2014).
101. Srivastava, R. et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 367, 115-123 (2012).
102. Brickshawana, A. et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol. 13, 795-806 (2014).
103. Ngo, S. T., Steyn, F. J. & McCombe, P. A. Gender differences in autoimmune disease. Front. Neuroendocrinol. 35, 347-369 (2014).
104. Voskuhl, R. Sex differences in autoimmune diseases. Biol. Sex Differ. 2, 1 (2011).
105. Stephan, A. H., Barres, B. A. & Stevens, B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369-389 (2012).
106. Clarke, L. E. & Barres, B. A. Emerging roles of astrocytes in neural circuit development. Nature Rev. Neurosci. 14, 311-321 (2013).
107. Rappold, P. M. & Tieu, K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 7, 413-423 (2010).
108. Failli, V. et al. Functional neurological recovery after spinal cord injury is impaired in patients with infections. Brain 135, 3238-3250 (2012).
109. Gold, R., Linington, C. & Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953-1971 (2006).
110. Hansen, R. R. & Malcangio, M. Astrocytes-multitaskers in chronic pain. Eur. J. Pharmacol. 716, 120-128 (2013).
111. Paradise, M. B., Naismith, S. L., Norrie, L. M., Graeber, M. B. & Hickie, I. B. The role of glia in late-life depression. Int. Psychogeriatr. 24, 1878-1890 (2012).
112. Martin, J. L., Magistretti, P. J. & Allaman, I. Regulation of neurotrophic factors and energy metabolism by antidepressants in astrocytes. Curr. Drug Targets 14, 1308-1321 (2013).
113. Czeh, B. & Di Benedetto, B. Antidepressants act directly on astrocytes: evidences and functional consequences. Eur. Neuropsychopharmacol 23, 171-185 (2013).
114. Chung, W. S. et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504, 394-400 (2013).
115. Miller, D. B. & O'Callaghan, J. P. Depression, cytokines, and glial function. Metabolism 54, 33-38 (2005).
116. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Rev. Neurosci. 9, 46-56 (2008).
117. Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446-457 (2010).
118. Irwin, M. R. & Cole, S. W. Reciprocal regulation of the neural and innate immune systems. Nature Rev. Immunol. 11, 625-632 (2011).
119. Bauer, S., Kerr, B. J. & Patterson, P. H. The neuropoietic cytokine family in development, plasticity, disease and injury. Nature Rev. Neurosci. 8, 221-232 (2007).
120. Deverman, B. E. & Patterson, P. H. Cytokines and CNS development. Neuron 64, 61-78 (2009).
121. Patterson, P. H. Maternal infection and autism. Brain Behav. Immun. 26, 393 (2012).
122. Brenner, M. et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nature Genet. 27, 117-120 (2001).
123. Messing, A., Brenner, M., Feany, M. B., Nedergaard, M. & Goldman, J. E. Alexander disease. J. Neurosci. 32, 5017-5023 (2012).
124. Lobsiger, C. S. & Cleveland, D. W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nature Neurosci. 10, 1355-1360 (2007).
125. Nagai, M. et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature Neurosci. 10, 615-622 (2007).
126. Yamanaka, K. et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nature Neurosci. 11, 251-253 (2008).
127. Myer, D. J., Gurkoff, G. G., Lee, S. M., Hovda, D. A. & Sofroniew, M. V. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 129, 2761-2772 (2006).
128. Sahni, V. et al. BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury. J. Neurosci. 30, 1839-1855 (2010).
129. Shimada, I. S., Borders, A., Aronshtam, A. & Spees, J. L. Proliferating reactive astrocytes are regulated by Notch-1 in the peri-infarct area after stroke. Stroke 42, 3231-3237 (2011).
130. Shimada, I. S., Lecomte, M. D., Granger, J. C., Quinlan, N. J. & Spees, J. L. Self-renewal and differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from the cortical peri-infarct area after stroke. J. Neurosci. 32, 7926-7940 (2012).
131. Meeuwsen, S., Persoon-Deen, C., Bsibsi, M., Ravid, R. & van Noort, J. M. Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli. Glia 43, 243-253 (2003).
132. Jensen, C. J., Massie, A. & De Keyser, J. Immune players in the CNS: the astrocyte. J. Neuroimmune Pharmacol. 8, 824-839 (2013).
133. Cooley, I. D., Chauhan, V. S., Donneyz, M. A. & Marriott, I. Astrocytes produce IL-19 in response to bacterial challenge and are sensitive to the immunosuppressive effects of this IL-10 family member. Glia 62, 818-828 (2014).
134. Pitter, K. L. et al. The SHH/Gli pathway is reactivated in reactive glia and drives proliferation in response to neurodegeneration-induced lesions. Glia 62, 1595-1607 (2014).
135. Sarafian, T. A. et al. Disruption of astrocyte STAT3 signaling decreases mitochondrial function and increases oxidative stress in vitro. PLoS ONE 5, e9532 (2010).
136. Hong, P., Jiang, M. & Li, H. Functional requirement of dicer1 and miR-17-5p in reactive astrocyte proliferation after spinal cord injury in the mouse. Glia 62, 2044-2060 (2014).
137. Krumbholz, M. et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201, 195-200 (2005).